
Sign up to save your podcasts
Or


f you’ve ever wondered whether single-arm studies are “good enough” for regulators or HTA bodies, this episode will challenge your assumptions. Anja Schiel, one of Europe’s leading voices at the regulator–HTA interface, explains why comparisons matter, where single-arm designs break down, and what smarter alternatives exist.
You’ll walk away with:
✔ A clearer understanding of the limits of single-arm trials
✔ Practical strategies for choosing comparators that strengthen your evidence package
✔ Insight into adaptive and hybrid designs that balance efficiency with rigor
✔ A regulator/HTA insider’s perspective on what decision-makers really need from statisticians
00:01:36 – Meet Anja Schiel and learn how she bridges regulation and HTA
00:02:28 – Why connecting regulators and HTA bodies early matters for drug development
00:06:07 – Where single-arm studies often fall short in real-world decision-making
00:08:01 – What accelerated approvals have taught us about assumptions in trial design
00:10:17 – Why comparison—not just randomization—is at the heart of sound evidence
00:12:12 – The pitfalls of relying on literature-based or naïve comparisons
00:16:54 – How regulators and HTA approach evidence differently
00:17:00 – What “concurrent control” really means and why it’s crucial
00:20:33 – Strategic thinking when selecting comparators for long-term value
00:26:00 – The role of adaptive and hybrid designs in modern trials
00:33:59 – Ethical considerations when trial designs fall short
00:36:26 – Why rare diseases demand smarter collaboration and evidence planning
00:40:25 – Communicating study objectives and estimands clearly for all stakeholders
00:44:55 – Final takeaways: how statisticians can lead the push for better designs
🔗 The Effective Statistician Academy – I offer free and premium resources to help you become a more effective statistician.
🔗 Medical Data Leaders Community – Join my network of statisticians and data leaders to enhance your influencing skills.
🔗 My New Book: How to Be an Effective Statistician - Volume 1 – It’s packed with insights to help statisticians, data scientists, and quantitative professionals excel as leaders, collaborators, and change-makers in healthcare and medicine.
🔗 PSI (Statistical Community in Healthcare) – Access webinars, training, and networking opportunities.
Join the Conversation:
Did you find this episode helpful? Share it with your colleagues and let me know your thoughts! Connect with me on LinkedIn and be part of the discussion.
Subscribe & Stay Updated:
Never miss an episode! Subscribe to The Effective Statistician on your favorite podcast platform and continue growing your influence as a statistician.
By Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry4.4
99 ratings
f you’ve ever wondered whether single-arm studies are “good enough” for regulators or HTA bodies, this episode will challenge your assumptions. Anja Schiel, one of Europe’s leading voices at the regulator–HTA interface, explains why comparisons matter, where single-arm designs break down, and what smarter alternatives exist.
You’ll walk away with:
✔ A clearer understanding of the limits of single-arm trials
✔ Practical strategies for choosing comparators that strengthen your evidence package
✔ Insight into adaptive and hybrid designs that balance efficiency with rigor
✔ A regulator/HTA insider’s perspective on what decision-makers really need from statisticians
00:01:36 – Meet Anja Schiel and learn how she bridges regulation and HTA
00:02:28 – Why connecting regulators and HTA bodies early matters for drug development
00:06:07 – Where single-arm studies often fall short in real-world decision-making
00:08:01 – What accelerated approvals have taught us about assumptions in trial design
00:10:17 – Why comparison—not just randomization—is at the heart of sound evidence
00:12:12 – The pitfalls of relying on literature-based or naïve comparisons
00:16:54 – How regulators and HTA approach evidence differently
00:17:00 – What “concurrent control” really means and why it’s crucial
00:20:33 – Strategic thinking when selecting comparators for long-term value
00:26:00 – The role of adaptive and hybrid designs in modern trials
00:33:59 – Ethical considerations when trial designs fall short
00:36:26 – Why rare diseases demand smarter collaboration and evidence planning
00:40:25 – Communicating study objectives and estimands clearly for all stakeholders
00:44:55 – Final takeaways: how statisticians can lead the push for better designs
🔗 The Effective Statistician Academy – I offer free and premium resources to help you become a more effective statistician.
🔗 Medical Data Leaders Community – Join my network of statisticians and data leaders to enhance your influencing skills.
🔗 My New Book: How to Be an Effective Statistician - Volume 1 – It’s packed with insights to help statisticians, data scientists, and quantitative professionals excel as leaders, collaborators, and change-makers in healthcare and medicine.
🔗 PSI (Statistical Community in Healthcare) – Access webinars, training, and networking opportunities.
Join the Conversation:
Did you find this episode helpful? Share it with your colleagues and let me know your thoughts! Connect with me on LinkedIn and be part of the discussion.
Subscribe & Stay Updated:
Never miss an episode! Subscribe to The Effective Statistician on your favorite podcast platform and continue growing your influence as a statistician.

78,335 Listeners

32,111 Listeners

30,667 Listeners

43,709 Listeners

9,529 Listeners

498 Listeners

176 Listeners

350 Listeners

9,152 Listeners

6,072 Listeners

29,216 Listeners

19 Listeners

3,080 Listeners

16 Listeners

26 Listeners